anidulafungin anidulafungin anidulafungin (inn): 42 (trade names eraxis, ecalta) is a semisynthetic echinocandin used as an antifungal drug. it was previously known as ly303366. it may also have application in treating invasive aspergillus infection when used in combination with voriconazole. it is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)-β-d-glucan synthase, an enzyme important to the synthesis of the fungal cell wall. anidulafunginclinical datapronunciation/eɪˌnɪdjʊləˈfʌndʒɪn/ ay-nid-yuu-lə-fun-jin trade nameseraxis, ecaltaother names(4r,5s)-4,5-dihydroxy-n2-carbonyl]-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline cyclic (6→1)-peptide1--4-yl]carbonyl]-l-ornithine]echinocandin bahfs/drugs.commonographlicense data eu ema: by inn us fda: anidulafungin routes ofadministrationintravenousatc codej02ax06 (who) legal statuslegal status in general: ℞ (prescription only) pharmacokinetic databioavailability100% (intravenous use only)protein bindingextensive (>99%)metabolismhepatic metabolism not observed, cyp system not involvedelimination half-life27 hours; 40–50 hours (terminal)excretionfeces (~30%), urine (<1%)identifiers iupac name n--11,20,21,25-tetrahydroxy-3,15-bis-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricycloheptacosan-18-yl]- 4-benzamide cas number166663-25-8 ypubchem cid166548drugbankdb00362 ychemspider21106258 yunii9hlm53094ikeggd03211 nchebichebi:55346 nchemblchembl1630215 ncomptox dashboard (epa)dtxsid50873201 echa infocard100.184.856 chemical and physical dataformulac58h73n7o17molar mass1140.254 g·mol−13d model (jsmol)interactive image smiles cccccoc1ccc(cc1)c2ccc(cc2)c3ccc(cc3)c(=o)n6c(o)(o)nc(=o)c4(o)(c)cn4c(=o)c(nc(=o)c(nc(=o)c5c(o)cn5c(=o)c(nc6=o)(c)o)(o)(o)c7ccc(o)cc7)(c)o inchi inchi=1s/c58h73n7o17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77h,5-7,24-28h2,1-4h3,(h,59,74)(h,60,75)(h,61,78)(h,62,76)(h,63,79)/t29-,30+,31+,39+,41-,42?,43+,44?,45?,46?,47?,48-,49+,50+,54+/m0/s1 ykey:jhvamhsqvvqiot-qzndwxlfsa-n y ny (what is this?) (verify) it is on the world health organization's list of essential medicines. indications candidemia and other forms of invasive candida infections (intra-abdominal abscess and peritonitis) esophageal candidiasis anidulafungin has not been studied in endocarditis, osteomyelitis, and meningitis due to candida, and has not been studied in sufficient numbers of neutropenic patients to determine efficacy in this group. pharmacodynamics and pharmacokinetics anidulafungin significantly differs from other antifungals in that it undergoes chemical degradation to inactive forms at body ph and temperature. because it does not rely on enzymatic degradation or hepatic or renal excretion, the drug is safe to use in patients with any degree of hepatic or renal impairment. volume of distribution: 30–50 l. anidulafungin is not evidently metabolized by the liver. this specific drug undergoes slow chemical hydrolysis to an open-ring peptide which lacks antifungal activity. the half-life of the drug is 27 hours. about 30% is excreted in the feces (10% as unchanged drug). less than 1% is excreted in the urine. mechanism of action anidulafungin inhibits glucan synthase, an enzyme important in the formation of (1→3)-β-d-glucan, a major fungal cell wall component. glucan synthase is not present in mammalian cells, so it is an attractive target for antifungal activity. semisynthesis anidulafungin is manufactured via semi-synthesis. the starting material is echinocandin b (a lipopeptide fermentation product of aspergillus nidulans or the closely related species, a. rugulosus), which undergoes deacylation (cleavage of the linoleoyl side chain) by the action of a deacylase enzyme from the bacterium actinoplanes utahensis; in three subsequent synthetic steps, including a chemical reacylation, the antifungal drug anidulafungin is synthesized. history anidulafungin was originally discovered at lilly laboratories by turner and debono and licensed to vicuron pharmaceuticals who submitted it to the fda. pfizer acquired the drug upon its acquisition of vicuron in the fall of 2005. pfizer gained approval by the food and drug administration (fda) on february 21, 2006.